---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-061875"
form_type: "8-K"
ticker: "LIMN"
cik: "0001971387"
company_name: "Liminatus Pharma, Inc."
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T22:59:38.662489+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Liminatus Pharma provides update on lead asset IBA101; IND filing H2 2025

## Summary
- IBA101 is a next-generation CD47 blockade designed to avoid anemia and thrombocytopenia seen with first-generation drugs.
- Preclinical data show IBA101 plus PD-1/PD-L1 inhibitors gave 2-3x higher complete response rates vs monotherapy.
- IND preparation begins H2 2025 with simultaneous submissions to U.S. FDA and Korea MFDS planned.
- Phase 1 first-in-human study in advanced solid tumors (starting with NSCLC) expected to launch in late 2026.
- Company completed SPAC merger with IRIS Acquisition Corp. and began trading on Nasdaq in May 2025.

## SEC filing metadata
- accession: 0001104659-25-061875
- form_type: 8-K
- ticker: LIMN
- cik: 0001971387
- company_name: Liminatus Pharma, Inc.
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/0001104659-25-061875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971387/000110465925061875/tm2518647d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-061875
- JSON: https://secwatch.observer/filing/0001104659-25-061875.json
- Plain text: https://secwatch.observer/filing/0001104659-25-061875.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.